These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36446780)

  • 1. EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis.
    Verma A; Singh A; Singh MP; Nengroo MA; Saini KK; Satrusal SR; Khan MA; Chaturvedi P; Sinha A; Meena S; Singh AK; Datta D
    Nat Commun; 2022 Nov; 13(1):7344. PubMed ID: 36446780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
    Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
    Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
    Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
    Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
    Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
    Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.
    Yomtoubian S; Lee SB; Verma A; Izzo F; Markowitz G; Choi H; Cerchietti L; Vahdat L; Brown KA; Andreopoulou E; Elemento O; Chang J; Inghirami G; Gao D; Ryu S; Mittal V
    Cell Rep; 2020 Jan; 30(3):755-770.e6. PubMed ID: 31968251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.
    Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z
    Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model.
    Monterroza L; Parrilla MM; Samaranayake SG; Rivera-Rodriguez DE; Yoon SB; Bommireddy R; Hosten J; Barragan LC; Marcus A; Dobosh BS; Selvaraj P; Tirouvanziam R
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
    Au SL; Wong CC; Lee JM; Wong CM; Ng IO
    PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway.
    Chien YC; Liu LC; Ye HY; Wu JY; Yu YL
    Am J Cancer Res; 2018; 8(3):422-434. PubMed ID: 29636998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 mutation is associated with the development of visceral metastasis by enhancing proliferation and invasion and inhibiting apoptosis in breast cancer cells.
    Wu F; Li N; Wu X; Chen M; Huang W; Chen X; Hong Y; Wang L; Chen K; Lin L; You M; Liu J
    BMC Cancer; 2024 Sep; 24(1):1166. PubMed ID: 39300407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional relationship of SNP (Ala490Thr) of an epigenetic gene
    Gautam N; Verma H; Choudhary S; Kaur S; Silakari O
    J Genet; 2021; 100():. PubMed ID: 34825659
    [No Abstract]   [Full Text] [Related]  

  • 12. Analysis of EZH2 Genetic Variants on Triple-Negative Breast Cancer Susceptibility and Pathology.
    Liu LC; Chien YC; Wu GW; Hua CH; Tsai IC; Hung CC; Wu TK; Pan YR; Yang SF; Yu YL
    Int J Med Sci; 2022; 19(6):1023-1028. PubMed ID: 35813302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
    Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
    J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies.
    Mei H; Wu H; Yang J; Zhou B; Wang A; Hu C; Qi S; Jiang Z; Zou F; Wang B; Liu F; Chen Y; Wang W; Liu J; Liu Q
    Signal Transduct Target Ther; 2023 Jan; 8(1):18. PubMed ID: 36642705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 induces the expression of miR-1301 as a negative feedback control mechanism in triple negative breast cancer.
    Wu Q; Chen Z; Zhang G; Zhou W; Peng Y; Liu R; Chen C; Feng J
    Acta Biochim Biophys Sin (Shanghai); 2018 Jul; 50(7):693-700. PubMed ID: 29790898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2-mediated H3K27me3 enrichment on the lncRNA MEG3 promoter regulates the growth and metastasis of glioma cells by regulating miR-21-3p.
    Qin WX; Shi Y; Zhu D; Li YP; Chen YH; Cui J; Cui GY; Pan JX; Ren ZY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3204-3214. PubMed ID: 32271438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The possible role of EZH2 and DNMT1 polymorphisms in sporadic triple-negative breast carcinoma in southern Chinese females.
    Tao R; Chen Z; Wu P; Liu C; Peng Y; Zhao W; Hu C; Feng J
    Tumour Biol; 2015 Dec; 36(12):9849-55. PubMed ID: 26162541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
    Holm K; Grabau D; Lövgren K; Aradottir S; Gruvberger-Saal S; Howlin J; Saal LH; Ethier SP; Bendahl PO; Stål O; Malmström P; Fernö M; Rydén L; Hegardt C; Borg Å; Ringnér M
    Mol Oncol; 2012 Oct; 6(5):494-506. PubMed ID: 22766277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade.
    Hoffmann F; Niebel D; Aymans P; Ferring-Schmitt S; Dietrich D; Landsberg J
    Clin Epigenetics; 2020 Feb; 12(1):24. PubMed ID: 32041674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.
    Nie L; Wei Y; Zhang F; Hsu YH; Chan LC; Xia W; Ke B; Zhu C; Deng R; Tang J; Yao J; Chu YY; Zhao X; Han Y; Hou J; Huo L; Ko HW; Lin WC; Yamaguchi H; Hsu JM; Yang Y; Pan DN; Hsu JL; Kleer CG; Davidson NE; Hortobagyi GN; Hung MC
    Nat Commun; 2019 Nov; 10(1):5114. PubMed ID: 31704972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.